Friday, April 03, 2020 10:56:56 AM
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher
Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.
The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.
Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.
Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 03, 2020 06:08 ET (10:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
New York Yankees and Duke Basketball
Recent ZNTL News
- Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/03/2024 10:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:00:53 AM
- Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 11:16:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 11:04:29 AM
- Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:01:39 PM
- Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:05:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:03:04 AM
- Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2024 09:30:00 PM
- Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 • GlobeNewswire Inc. • 04/02/2024 08:05:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2024 09:30:00 PM
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 11:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/29/2024 10:20:16 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/29/2024 10:14:29 PM
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:08:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:04:11 PM
- Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:12:34 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:43:38 AM
- Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/13/2024 12:00:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM